- Home
- JRS vs AKBA Comparison
JRS vs AKBA Comparison
Compare JRS & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JRS | AKBA |
|---|---|---|
| Founded | 2001 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 237.8M | 251.0M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | JRS | AKBA |
|---|---|---|
| Price | $8.67 | $1.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.67 |
| AVG Volume (30 Days) | 86.1K | ★ 4.1M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 8.87% | N/A |
| EPS Growth | N/A | ★ 93.94 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.12 | $0.82 |
| 52 Week High | $8.75 | $3.81 |
Technical Indicators
Market Signals| Indicator | JRS | AKBA |
|---|---|---|
| Relative Strength Index (RSI) | 59.84 | 46.66 |
| Support Level | $8.05 | $1.16 |
| Resistance Level | $8.75 | $1.52 |
| Average True Range (ATR) | 0.11 | 0.07 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 71.43 | 7.59 |
Price Performance
Historical ComparisonAbout JRS Nuveen Real Estate Income Fund of Beneficial Interest
Nuveen Real Estate Income Fund is a diversified closed-end investment company. The Fund s investment objective is to provide total return through high current income and capital appreciation.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.